Updated March 29 at 12:29am

Sign up to receive Providence Business News' newsletters
and breaking news alerts.  

technology

Covidien’s lung cancer diagnosis technology earns ACCP commendation

Posted:

MANSFIELD – Biotechnology company and medical device maker Covidien Plc, has earned a commendation from the American College of Chest Physicians for the first-of-its-kind technology superDimension Electromagnetic Navigation Brochoscopy system.

The technology, which diagnoses early lung cancer, has been included in the new American College of Chest Physicians guidelines to aid in diagnosing and managing lung cancer.

According to Covidien, the evidence-based clinical practice guidelines were released by the ACCP earlier this month.

“Electromagnetic Navigation Bronchoscopy has over eight years of clinical use in the United States,” Dr. David S. Wilson, medical director of the Lung Institute at Columbus Regional Health, said in a statement.

“The diagnosis of lung cancer guidelines from the American College of Chest Physicians, which specifically state the increased yields of ENB and historic safety of bronchoscopy, make ENB a preferred diagnostic procedure for lung cancer,” Wilson said. “ENB has become a platform technology for further diagnostics and therapeutics in the lung periphery. Guideline status marks a new era of bronchoscopy made possible by ENB.”

Through its proprietary software and electromagnetic technology, the superDimension ENB system uses the patient’s natural airway access of the lungs to “safely locate and more easily obtain a tissue sample of a lesion, even in the areas of the lung that are difficult to reach and where two-thirds of all lung lesions cannot be accessed by a traditional broncoscope,” said the Covidien release.

“Cancer patients, in general, benefit from diagnosis of their condition at the earliest possible stage, which may lead to earlier treatments and, potentially, more favorable outcomes,” Bryan Hanson, group president of surgical solutions at Covidien, said in a statement. “ENB is a minimally invasive approach to accessing difficult-to-reach lung lesions, which can lead to earlier diagnosis and treatment of cancer.

“Covidien is committed to developing innovative medical technologies that improve the patient’s quality of life, while reducing the overall cost of healthcare,” Hanson added. “Covidien’s superDimension technology is a great example of this commitment.”

Since the system launched, more than 40,000 patients have undergone a superDimension ENB procedure at over 500 leading medical facilities worldwide.

Biotechnology company, device maker Covidien Plc

Comments

No comments on this story | Please log in to comment by clicking here
Please log in or register to add your comment
Latest News